$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000154422716000010 Filed on May 05, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$189.0K	$146.0K	$15.00K
YoY Change	530.0%	873.33%
Cost Of Revenue	$1.233M	$1.176M	$35.00K
YoY Change	962.93%	3260.0%
Gross Profit	-$1.044M	-$1.030M	-$20.00K
YoY Change	1113.95%	5050.0%
Gross Profit Margin	-552.38%	-705.48%	-133.33%
Selling, General & Admin	$11.21M	$14.45M	$11.05M
YoY Change	-14.21%	30.85%	268.2%
% of Gross Profit
Research & Development	$5.987M	$5.955M	$5.747M
YoY Change	48.89%	3.62%	23.54%
% of Gross Profit
Depreciation & Amortization	$600.0K	$504.0K	$227.0K
YoY Change	200.0%	122.03%	243.94%
% of Gross Profit
Operating Expenses	$18.43M	$21.59M	$16.83M
YoY Change	7.13%	28.27%	119.97%
Operating Profit	-$18.24M	-$21.44M	-$16.81M
YoY Change	6.21%	27.51%	119.78%
Interest Expense	-$260.0K	-$220.0K	-$430.0K
YoY Change	-10.34%	-48.84%	186.67%
% of Operating Profit
Other Income/Expense, Net	-$22.00K	-$27.00K	$34.00K
YoY Change	-21.43%	-179.41%	-440.0%
Pretax Income	-$18.52M	-$21.68M	-$17.21M
YoY Change	5.88%	26.02%	120.31%
Income Tax	$50.00K	$75.00K	$0.00
% Of Pretax Income
Net Earnings	-$18.57M	-$21.76M	-$17.21M
YoY Change	6.16%	26.46%	120.19%
Net Earnings / Revenue	-9824.34%	-14902.74%	-114706.67%
Basic Earnings Per Share
Diluted Earnings Per Share	-$142.80	-$181.30	-$143.40
COMMON SHARES
Basic Shares Outstanding	27.33M shares	27.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$147.7M	$110.1M	$169.3M
YoY Change	-5.08%	-34.97%	89.16%
Cash & Equivalents	$95.89M	$20.48M	$134.7M
Short-Term Investments	$51.80M	$89.60M	$34.60M
Other Short-Term Assets	$2.500M	$2.600M	$2.000M
YoY Change	-28.57%	30.0%	233.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$150.1M	$112.7M	$171.3M
YoY Change	-5.69%	-34.19%	90.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.149M	$8.667M	$4.200M
YoY Change	93.65%	106.36%	249.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$215.0K	$200.0K
YoY Change		7.5%	-85.74%
Other Assets	$23.00K	$400.0K	$100.0K
YoY Change		300.0%	0.0%
Total Long-Term Assets	$8.611M	$9.321M	$4.500M
YoY Change	62.72%	107.13%	67.1%
TOTAL ASSETS
Total Short-Term Assets	$150.1M	$112.7M	$171.3M
Total Long-Term Assets	$8.611M	$9.321M	$4.500M
Total Assets	$158.7M	$122.1M	$175.8M
YoY Change	-3.49%	-30.57%	89.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.466M	$4.218M	$2.500M
YoY Change	-17.44%	68.72%	28.67%
Accrued Expenses	$8.300M	$7.600M	$4.100M
YoY Change	80.43%	85.37%	-5.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.74M	$11.81M	$6.600M
YoY Change	41.35%	78.89%	4.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.400M	$1.400M	$100.0K
YoY Change	839.6%	1300.0%	35.14%
Total Long-Term Liabilities	$1.400M	$1.400M	$100.0K
YoY Change	839.6%	1300.0%	35.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.74M	$11.81M	$6.600M
Total Long-Term Liabilities	$1.400M	$1.400M	$100.0K
Total Liabilities	$12.17M	$13.22M	$6.700M
YoY Change	57.03%	97.25%	5.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.2M	-$189.7M
YoY Change	60.94%
Common Stock	$36.00K	$27.00K
YoY Change	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$146.6M	$108.8M	$169.1M
YoY Change
Total Liabilities & Shareholders Equity	$158.7M	$122.1M	$175.8M
YoY Change	-3.49%	-30.57%	89.52%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$18.57M	-$21.76M	-$17.21M
YoY Change	6.16%	26.46%	120.19%
Depreciation, Depletion And Amortization	$600.0K	$504.0K	$227.0K
YoY Change	200.0%	122.03%	243.94%
Cash From Operating Activities	-$15.92M	-$15.41M	-$14.39M
YoY Change	32.01%	7.06%	190.2%
INVESTING ACTIVITIES
Capital Expenditures	$500.0K	$370.0K	$389.0K
YoY Change	-34.21%	-4.88%
Acquisitions
YoY Change
Other Investing Activities	$37.78M	-$6.970M	$18.28M
YoY Change	-172.25%	-138.13%	-311.57%
Cash From Investing Activities	$37.28M	-$7.336M	$17.89M
YoY Change	-170.27%	-141.0%	-307.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$53.90M	$0.00	$124.1M
YoY Change		-100.0%	140.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	54.06M	$0.00	$124.8M
YoY Change	8346.87%	-100.0%	141.55%
NET CHANGE
Cash From Operating Activities	-15.92M	-$15.41M	-$14.39M
Cash From Investing Activities	37.28M	-$7.336M	$17.89M
Cash From Financing Activities	54.06M	$0.00	$124.8M
Net Change In Cash	75.42M	-$22.75M	$128.3M
YoY Change	-216.98%	-117.73%	237.06%
FREE CASH FLOW
Cash From Operating Activities	-$15.92M	-$15.41M	-$14.39M
Capital Expenditures	$500.0K	$370.0K	$389.0K
Free Cash Flow	-$16.42M	-$15.78M	-$14.78M
YoY Change	28.08%	6.74%	198.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27328779	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2016Q1	ovas	Allocated Share Based Compensation Expense Reversed AllocatedShareBasedCompensationExpenseReversed	800000	USD
CY2015Q1	ovas	Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters	345000	shares
CY2016Q1	ovas	Numberof Treatments NumberofTreatments	1	treatment
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2016Q1	ovas	Potential Treatments In Development PotentialTreatmentsInDevelopment	2	treatment
CY2015Q1	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	724000	USD
CY2016Q1	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	0	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3352000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4218000	USD
CY2015Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7891000	USD
CY2016Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7589000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2420000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2924000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-170000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	294910000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	298499000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	171000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	295000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4108000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5653000	shares
CY2015Q4	us-gaap	Assets Assets	138613000	USD
CY2016Q1	us-gaap	Assets Assets	122060000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	129861000	USD
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27296747	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27307759	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27296747	shares
CY2016Q1	us-gaap	Assets Current AssetsCurrent	112739000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	126662000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	110088000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	170000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	37000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126832000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	110095000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	81400000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	36100000	USD
CY2015Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	43	investment
CY2016Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	18	investment
CY2016Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	18	investment
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6414000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134698000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43224000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20478000	USD
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	110100000	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27307759	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17181000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21595000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	35000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	1176000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	520000	USD
CY2016Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1409000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	227000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	504000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2015Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138613000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122060000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-22746000	USD
CY2016Q1	us-gaap	Equity Method Investments EquityMethodInvestments	215000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17206000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21683000	USD
CY2015Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-471000	USD
CY2016Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-391000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-657000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	378000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3528000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	721000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	239000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-470000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-88000	USD
CY2015Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	44000	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	174000	USD
CY2015Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	38000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	11763000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	13216000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11243000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11807000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	128284000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124787000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17891000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7336000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14394000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15410000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-17206000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-21758000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	16828000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	21585000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16813000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21439000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	25000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	163000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27000	USD
CY2015Q1	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	750000	USD
CY2015	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
CY2016Q1	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	750000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	389000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	370000	USD
CY2015Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	27118000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3002000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2542000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124100000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124063000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	19030000	USD
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	20814000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10733000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11591000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8313000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8667000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5747000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5955000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	197000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	109000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167917000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189675000	USD
CY2015Q1	us-gaap	Revenues Revenues	15000	USD
CY2016Q1	us-gaap	Revenues Revenues	146000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11046000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14454000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6367000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3551000	USD
CY2015Q1	us-gaap	Share Price SharePrice	50
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	83438000	USD
CY2016Q1	us-gaap	Short Term Investments ShortTermInvestments	89610000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2645000	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	126850000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	108844000	USD
CY2016Q1	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26588000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27301000	shares
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles, which require management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-16-000010-index-headers.html	Edgar Link	pending
0001544227-16-000010-index.html	Edgar Link	pending
0001544227-16-000010.txt	Edgar Link	pending
0001544227-16-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hstockoptions.jpg	Edgar Link	pending
ovas-20160331.xml	Edgar Link	completed
ovas-20160331.xsd	Edgar Link	pending
ovas-20160331x10q.htm	Edgar Link	pending
ovas-20160331xex101.htm	Edgar Link	pending
ovas-20160331xex102.htm	Edgar Link	pending
ovas-20160331xex103.htm	Edgar Link	pending
ovas-20160331xex104.htm	Edgar Link	pending
ovas-20160331xex105.htm	Edgar Link	pending
ovas-20160331xex106.htm	Edgar Link	pending
ovas-20160331xex107.htm	Edgar Link	pending
ovas-20160331xex108.htm	Edgar Link	pending
ovas-20160331xex109.htm	Edgar Link	pending
ovas-20160331xex311.htm	Edgar Link	pending
ovas-20160331xex312.htm	Edgar Link	pending
ovas-20160331xex321.htm	Edgar Link	pending
ovas-20160331xex322.htm	Edgar Link	pending
ovas-20160331_cal.xml	Edgar Link	unprocessable
ovas-20160331_def.xml	Edgar Link	unprocessable
ovas-20160331_lab.xml	Edgar Link	unprocessable
ovas-20160331_pre.xml	Edgar Link	unprocessable
ovascienceheader.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2016 Q2 Form 10-Q Financial Statement

#000154422716000010 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2016 Q2 Form 10-Q Financial Statement

#000154422716000010 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst